Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow
- 15 April 2002
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (8) , 2005-2016
- https://doi.org/10.1200/jco.2002.08.003
Abstract
PURPOSE: To study the invasion-related molecule urokinase-type plasminogen activator receptor (u-PAR) expressed by disseminated tumor cells as a biologic predictor of poor survival in a large prospective series of patients with gastric cancer. PATIENTS AND METHODS: In 156 gastric cancer patients (prospective series), disseminated tumor cells in the bone marrow and the u-PAR expressed by these tumor cells were determined by cytokeratin (CK) 18 immunocytochemistry and u-PAR/CK18 double immunocytochemistry. RESULTS: In contrast to the mere detection of disseminated tumor cells at primary surgery, the additional evidence of u-PAR on these cells correlated significantly with pathologic T stage (P = .0474) and the expression of u-PAR (P = .0093) and plasminogen-activator inhibitor 1 (P = .0145) in the primary tumor (immunohistochemistry, χ2). Kaplan-Meier analysis revealed no association with prognosis for the mere detection of disseminated tumor cells. In contrast, a significant association was seen between detection of u-PAR on these cells and shorter disease-free (P < .0001) and overall survival (P < .0001). Multivariate analysis revealed that u-PAR on disseminated tumor cells at the time of primary surgery is an independent prognostic factor for disease-free (95% confidence interval [CI], 1.72 to 3.21; P = .024) and overall survival (P = .0049; relative risk, 2.89; 95% CI, 1.92 to 4.30). CONCLUSION: This is the first large study to show that u-PAR, detected on disseminated tumor cells in the bone marrow, is an independent prognostic parameter in gastric cancer, in contrast to the mere detection of minimal residual disease (MRD). u-PAR may be a promising marker to define a critical subpopulation of disseminated tumor cells and a target to eliminate MRD. Molecular phenotyping of MRD is critical for defining its individual clinical relevance.Keywords
This publication has 60 references indexed in Scilit:
- The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of diseaseInternational Journal of Cancer, 1996
- Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone MarrowJournal of Hematotherapy, 1994
- Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cellsHistochemistry and Cell Biology, 1993
- Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patientsThe Lancet, 1992
- Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.Journal of Clinical Oncology, 1991
- Prognostic Value of Immunocytologic Detection of Bone Marrow Metastases in NeuroblastomaNew England Journal of Medicine, 1991
- The Relationship Between Micrometastases in the Bone Marrow, Histopathologic Features of the Primary Tumor in Breast Cancer and PrognosisAmerican Journal of Clinical Pathology, 1988
- Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases.BMJ, 1987